Aura Biosciences (AURA) Stock Forecast & Price Target

Aura Biosciences is on track with its clinical development plans and has potential for positive results from its ongoing Phase 3 CoMpass trial for bel-sar, with robust statistical powering assumptions and strong alignment with regulatory and clinical endpoints. The completed enrollment of 108 patients provides a buffer against potential patient attrition and the potential for CoMpass to read out positively across different real-world effect sizes beyond the observed Phase 2 data. With a healthy cash position and upcoming data readouts, the company has potential for positive stock growth in the long-term, particularly with the potential for pricing power in a rare disease setting and opportunities for label expansion in other ocular indications. Investors should look for data readouts and durable reductions in recurrence rates in bladder cancer as key value inflection points.

Aura Biosciences is focusing on precision immunotherapies for solid tumors, but with limited financial resources, they have been forced to redirect capital towards more lucrative ocular oncology programs, potentially hindering the development and commercialization of their NMIBC program. Additionally, the success of their pivotal Phase 3 CoMpass trial for bel-sar in early choroidal melanoma rests on real-world adoption and pricing strategies, as well as potential partnerships for their NMIBC program and other ocular indications. Their current cash runway is only expected to last until 1H29, leading to questions about the long-term financial sustainability and timelines for their various programs.